04/05/20 PRESS RELEASE – immediate BCG Vaccine Clinical Trial in response to Covid-19 pandemic TASK008 – A placebo-controlled adaptive randomized controlled trial Caption of press photo: TASK nurse injects the first participant, watched closely by study leader Dr Caryn Upton and Professor Andreas Diacon, founder and CEO of TASK. TASK has just injected the…
TASK is a clinical research organisation based in Cape Town, South Africa with a focus on performing clinical trials. TASK provides assistance to efficiently conduct studies for diagnosis, treatment or prevention of tuberculosis, as well as other prevalent diseases such as asthma, osteoarthritis and vaccine studies, where new and improved treatments are urgently needed.
The company was founded in 2005 by Prof. Andreas Diacon to accelerate the development and evaluation of novel anti-tuberculosis drugs. TASK mainly collaborates with international NGOs, government funded consortia, academic centers and pharmaceutical companies on various drug development projects.
TASK now employs over 150 staff members, has invested in state of the art bio-safety level 3 laboratory capacity as well as a network of clinical sites in Cape Town and the Western Cape.